Results of a randomized study of early stage Hodgkin's disease using ABVD,EBVD, or MBVD

From January 1986 to December 1989, 157 previously untreated patients, with Hodgkin's disease stage I or II without bulky disease, were enrolled in a clinical comparative study. The objectives of the study were to compare the efficacy and safety of using epirubicine or mitoxantrone instead of adriamycin in the combination chemotherapy regimen ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine). The complete response rate was better in the patients treated with the ABVD or EBVD regimens compared to the MBVD arm. Also, differences in overall survival and relapse-free survival were better in the patients who received ABVD or EBVD compared to the MBVD regimen. Hematological, gastrointestinal and cardiac toxicity were similar in the three groups. Dose intensity, delays and complications were also similar in the three groups. The mitoxantrone-containing regimen was found to have less efficacy in comparison to the other regimens tested in the present study in patients with favorable stage I or II Hodgkin's disease. © 1995 Wi1ey-Liss Inc.     

Current strategies in the treatment of non-muscle-invasive bladder cancer

This review is based on a data search up to the end of January 2012 on strategies in the treatment of non-muscle-invasive bladder cancer. One of the authors was chairman of the guidelines writing committee of the European Association of Urology, and these guidelines served as a backbone. They are updated and adapted according to the most recent data. It is astonishing how much important data were published in the last 2 years. Many data have a high level of evidence and allow well-supported recommendations. However, recommendations are not given but the discussion for reflection on it is given in this article.